DVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DaVita is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who does not want to wait for an ideal entry. The stock is technically strong, but it is already extended and overbought, while sentiment is mixed and there is no fresh catalyst or financial detail strong enough to justify an immediate new long-term purchase at this level. If forced to act today, the better choice is to hold rather than buy aggressively.
DVA is in a clear bullish trend: MACD histogram is positive and expanding, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). However, RSI_6 at 95.487 is extremely overbought, which suggests the move has likely run ahead of near-term fundamentals and increases the chance of a pullback or consolidation. Price at 234.84 is near the R2 resistance at 238.686 and above the pivot at 220.356, showing strength but also limited immediate upside from a fresh entry. The recent pattern data implies only modest forward gains in the near term.
["Analysts have recently raised price targets across multiple firms after Q1 results.", "Deutsche Bank upgraded DVA to Buy from Hold, citing stronger revenue per treatment and treatment growth.", "UBS and other firms raised targets, indicating improved Wall Street confidence after earnings.", "Technical trend remains strongly bullish with MACD expansion and bullish moving-average alignment.", "Options flow is bullish, with call-heavy positioning and low put-call ratios."]
["RSI is extremely overbought, making the stock stretched for a new long-term entry.", "Hedge funds are reported as selling heavily over the last quarter.", "There is no recent news flow in the past week to drive a fresh catalyst.", "No recent congress trading data or influential insider buying signal is available to support the case.", "The stock is trading close to resistance, reducing immediate upside for an impatient buyer."]
No financial snapshot was available due to data error, so latest-quarter revenue and earnings trends cannot be directly confirmed here. The analyst commentary suggests Q1 was better than expected, with stronger non-acquired treatments, revenue per treatment, treatment growth, and raised FY26 guidance. Based on that, the latest quarter appears to have shown improving operating trends, but the full financial picture is incomplete in the provided data.
Recent analyst revisions trend positive: Deutsche Bank upgraded the stock to Buy and several firms raised price targets after Q1 results. However, most of the broader Wall Street coverage still sits at Hold or Equal Weight, which means the pros see improved fundamentals but not enough undervaluation to make it a universal buy. Net view: cautiously constructive, but not an outright consensus buy.
